PMID- 24524766
OWN - NLM
STAT- MEDLINE
DCOM- 20150220
LR  - 20210103
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 21
IP  - 21
DP  - 2014
TI  - Personalized peptide vaccine for treatment of advanced cancer.
PG  - 2332-45
AB  - The field of cancer immunotherapy has moved forward drastically in the past 20 
      years, since many tumor-associated antigens (TAA) have been identified. Although 
      various approaches for therapeutic cancer immunotherapies, including 
      peptide-based vaccines, have been developed and clinically examined, the 
      complexity and diversity of tumor cell characteristics and host immune cell 
      repertoires seem to limit the therapeutic efficacy of this treatment modality. 
      Considering the diversity of immune responses against heterogeneous tumor cells, 
      tailored selections of vaccine antigens appropriate for individual patients could 
      be a rational approach for developing effective cancer vaccines. We have 
      developed a novel immunotherapeutic approach called personalized peptide vaccine 
      (PPV), in which a maximum of four human leukocyte antigen (HLA)-matched vaccine 
      peptides were selected based on the pre-existing host immunity before 
      vaccination. We conducted a series of phase I and phase II clinical trials of 
      PPV, which have shown better antigen-specific immune responses and promising 
      clinical outcomes in patients with various types of advanced cancers. Further 
      randomized phase III trials would be recommended to prove the clinical benefits 
      of PPV. In addition, novel biomarkers for selecting patients who would benefit 
      most from PPV remain to be identified.
FAU - Sasada, Tetsuro
AU  - Sasada T
FAU - Yamada, Akira
AU  - Yamada A
FAU - Noguchi, Masanori
AU  - Noguchi M
FAU - Itoh, Kyogo
AU  - Itoh K
AD  - Department of Immunology and Immunotherapy, Kurume University School of Medicine, 
      67 Asahimachi, Kurume, Fukuoka 830-0011, Japan. tsasada@med.kurume-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Cancer Vaccines/chemistry/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Molecular Sequence Data
MH  - Neoplasms/immunology/*therapy
MH  - Precision Medicine
MH  - Vaccines, Subunit/chemistry/*therapeutic use
EDAT- 2014/02/15 06:00
MHDA- 2015/02/24 06:00
CRDT- 2014/02/15 06:00
PHST- 2013/01/10 00:00 [received]
PHST- 2013/05/24 00:00 [revised]
PHST- 2013/05/26 00:00 [accepted]
PHST- 2014/02/15 06:00 [entrez]
PHST- 2014/02/15 06:00 [pubmed]
PHST- 2015/02/24 06:00 [medline]
AID - CMC-EPUB-59030 [pii]
AID - 10.2174/0929867321666140205132936 [doi]
PST - ppublish
SO  - Curr Med Chem. 2014;21(21):2332-45. doi: 10.2174/0929867321666140205132936.